rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Multivariate analysis revealed age, Karnofsky performance score, extent of tumor resection, first-line treatment, year of diagnosis, and MGMT promoter methylation status were associated with survival in patients with IDH1(R132H) -nonmutant glioblastoma.
|
27088883 |
2016 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
R132H mutation of isocitrate dehydrogenase 1 (IDH1) is found in ~75% of low-grade gliomas and secondary glioblastomas as well as in several other types of cancer.
|
29792149 |
2018 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We found that both low-grade and high-grade (i.e., GBM) IDH1 R132H gliomas exhibit low Fn14 mRNA and protein levels compared to IDH1 WT gliomas.
|
29453678 |
2018 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Data showed that 53.7% (72/134) of cases showed mutations affecting codon 132 of IDH1, including 73.2% of LOs, 82.9% of AOs and three primary GBMs (6.5%).All IDH1 mutations were Arg132His.
|
22922798 |
2012 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Three GBM-O samples had IDH1 (p.R132H) mutations; two of these also demonstrated 1p/19q co-deletion and had a proneural transcriptional profile, a molecular signature characteristic of oligodendroglioma.
|
26757882 |
2016 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We evaluated nuclear cMYC protein levels and IDH1 (R132H) by immunohistochemistry in patients with oligodendroglioma/oligoastrocytomas (n = 20), astrocytomas (grade II) (n = 19), anaplastic astrocytomas (n = 21) or glioblastomas (n = 111).
|
23934175 |
2013 |
rs121913500
|
|
T |
0.800 |
GeneticVariation |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In the subgroup of 142 glioma patients characterized by IDH1-R132H status, METT/N ratio demonstrated a significant prognostic impact in IDH1-R132H wildtype astrocytomas and glioblastoma (P = 0.001).
|
29016947 |
2018 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A total of 15.3% of enrolled GBMs demonstrated loss of ATRX expression (ATRX-), 10.4% expressed an aberrant IDH1 R132H protein (IDH1+), and 48.4% exhibited p53 overexpression (p53+).
|
27478330 |
2016 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Isocitrate dehydrogenase (IDH) is mutated in >80% of lower-grade infiltrating gliomas in adults and in ~10% of glioblastomas, with IDH1 (R132H) being the most common mutation.
|
30221786 |
2019 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We analyzed patients with newly diagnosed GBM and excluded patients who presented with IDH1 R132H mutations.
|
29617848 |
2019 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We identified a small cohort of WHO grade II-III astrocytomas that harbored the IDH1 R132H mutation, as confirmed by both immunohistochemistry and molecular sequence analysis, which nonetheless had unexpectedly rapid recurrence and subsequent progression to glioblastoma.
|
28421459 |
2017 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
We prospectively analyzed the clinical data over the course of the disease, baseline MR imaging, and histological characteristics (p53 overexpression, the Ki67 proliferation index, and presence of the IDH1 R132H mutation), in glioblastomas treated in a single hospital from November 2012 to July 2014.
|
28073027 |
2017 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Low-grade gliomas (WHO II/III) had lower xCT expression than glioblastoma (p = 0.001), and tumors without IDH1 R132H mutation tended to have higher xCT levels (p = 0.07).
|
29404978 |
2018 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In addition, overexpression of IDH1-R132H in glioblastoma cell lines U87 and U251 led to reduced cell proliferation, migration and invasion, accompanied by increased apoptosis.
|
26860959 |
2016 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Expression of R132H mutational IDH1 in human U87 glioblastoma cells affects the SREBP1a pathway and induces cellular proliferation.
|
23011765 |
2013 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
This group showed absent IDH1-R132</span>H expression, which is characteristic of primary GBM.
|
22197544 |
2012 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Here we show that SREBPs were up-regulated in U87 human glioblastoma cells transfected with an IDH1(R132H)-expression plasmid.
|
24077277 |
2013 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mutation of the isocitrate dehydrogenase 1 (IDH1) gene at codon 132 has been identified in approximately 70% of low-grade (II and III) human gliomas and secondary glioblastomas, with the IDH1 R132H point mutation representing 92.7% of these mutations.
|
30502793 |
2018 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Somatic mutation of Isocitrate dehydrogenase 1 (IDH1) at the locus of R132 (IDH1 (R132H)) occurs in > 70% of WHO grade II-III gliomas and secondary glioblastomas.
|
22785212 |
2012 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Furthermore, SMab-1 specifically stained the IDH1-R132S-expressing glioblastoma cells in immunocytochemistry and immunohistochemistry, but did not react with IDH1-WT or IDH1-R132H-containing glioblastoma cells.
|
21352804 |
2011 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
A clonal IDH1 R132H mutation in the primary, a known GBM driver event, was detectable at only very low frequency in the recurrent tumour.
|
25732040 |
2015 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
In this study, we investigated which genes are differentially regulated in IDH1 wild type (IDH1WT) or IDH1 R132H mutation (IDH1R132H) glioblastoma cells.
|
28445981 |
2017 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Mean CBF1 expression is significantly increased in isocitrate dehydrogenase 1 (IDH1) R132H mutant glioblastoma and serves as prognostic marker for prolonged overall survival in brain tumours, particularly after therapy with temozolomide.
|
28571041 |
2017 |
rs121913500
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Among the GBM cases it was noted that the IDH1 immunopositive tumors (R132H mutant protein; n=17) had a low MnSOD expression as opposed to IDH1 immunonegative tumors (n=106), which had high expression of MnSOD (p=0.0307).
|
26616112 |
2016 |